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Targeted molecular probes have been used to detect sporadic colonic dysplasia during con-
focal laser endomicroscopy (CLE) with promising results. This is a feasibility pilot study aim-
ing to assess the potential role of CLE combined with a fluorescent-labeled peptide to stain
and detect dysplasia associated with Ulcerative Colitis.
Method
A phage-derived heptapeptide with predicted high binding affinity for dysplastic tissue, was
synthesized and labeled with fluorescein. Eleven lesions with suspected dysplasia at endos-
copy were excised from nine patients with long-standing ulcerative colitis. Specimens were
sprayed with the peptide and examined by CLE. The CLE images were then compared to
the corresponding histological sections.
Results
At definitive histology, 4 lesions were diagnosed as inflammatory polyps, 6 as dysplastic
lesions and one as invasive cancer. In inflammatory polyps, the fluorescence signal came
from peri-cryptal spaces and crypt lumen due to passive accumulation of the peptide in
these areas. Dysplasia was associated with active binding of the peptide to dysplastic
colonocytes.
Conclusion
Ex vivo staining of ulcerative colitis-associated dysplasia using a fluorescent labeled molec-
ular probe and CLE is feasible. In vivo studies on larger populations are required to evaluate
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Introduction
Patients with long-standing ulcerative colitis (UC) have an increased risk of developing colo-
rectal cancer (CRC). This neoplasia has a cumulative incidence of 2%, 8% and 18% after 10, 20
and 30 years of disease, respectively [1]. Patients affected by long-standing UC are therefore
candidates for surveillance colonoscopy to detect dysplasia [2,3]. Other than in association
with polypoid lesions, dysplasia in UC can also develop in non-polypoid lesions or even within
unremarkable mucosa (invisible dysplasia) [4]. Therefore, enhanced optical imaging tech-
niques have been used to facilitate detection of dysplasia in these patients.
Chromo-endoscopy with indigo carmine or methylene blue has been particularly successful
in this setting. Indeed, this technique increases the probability of detecting dysplasia by 3 to
5-fold compared to random biopsies [5,6], and is now considered a crucial tool in the surveil-
lance of patients with inflammatory bowel diseases (IBD) [7].
Another contribution to this field was confocal laser endomicroscopy (CLE). This method
provides in vivo high-magnified images of microscopic details of the gastrointestinal mucosa
thereby enabling a diagnosis of early CR C and detection of dysplasia in UC patients [8,9].
Chromo-guided CLE has a high accuracy (97.8%) in the diagnosis of neoplastic changes in
these patients [10]. Recent years have seen a growing interest in the combined use of targeted
probes and new imaging technologies for early detection of cancer. Fluorescein-labeled probes,
such as antibodies against neoplastic antigens [11–14] or phage-derived peptides binding dys-
plastic tissue [15,16] have been used in combination with CLE [17]. These latter probes are
perhaps the most promising thanks to their low cost and limited immunogenicity, other than
the possibility of binding pre-malignant tissue [17]. In-vivo topical application of peptides has
been demonstrated to be safe, resulting in accurate staining of adenomatous colonic dysplasia
[15]. Consequently, these probes are promising candidates for the detection of dysplasia in sur-
veillance programmes in UC.
This is a feasibility pilot study aiming to investigate the potential role of CLE combined
with a fluorescent-labeled molecular probe to stain and detect dysplasia in patients with long-
standing UC.
Methods
Peptide synthesis and purification
The VRPMPLQ peptide [15] was synthesized on a BiotageSyroWave instrument, a system that
combines conventional room temperature and microwaves peptide synthesis, at 25 μmol scale.
Fluorescein conjugation was performed at the peptide N-terminus, via an aminohexanoic acid
linker, using standard9-fluorenylmethoxycarbonyl (Fmoc) chemistry protocols. Fmocdepro-
tection was carried out with 25% piperidine in DMF for 5 +10 min at 25˚C.Solutions of Fmoc-
AA, HOBT/HBTU, and DIPEA were prepared at concentrations of 0.5M, 0.45M, and 1M in
DMF, respectively. Coupling was performed with a 5-fold excess of Fmoc-AA-OH with 1:1:2
AA/HOBT-HBTU/DIPEA for 30 min at 25˚C. Cleavage was carried out with 94:1:2.5:2.5 TFA/
H2O/TIS/Thioanisole for 3 hours at 25˚C, followed by precipitation and washings in tert-butyl
methyl ether. Peptide analysis and purification were performed with a combined HPLC-ESI
+-MS system (high performance liquid chromatography(Gilson, Middleton, WI, USA)
Detection of dysplasia in ulcerative colitis by targeted fluorescent peptide and confocal endomicroscopy
PLOS ONE | https://doi.org/10.1371/journal.pone.0180509 June 30, 2017 2 / 9
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
coupled with a positiveelectrospray mass spectrometry ionization instrument (FlexarSQ 300
ESI+-MS, Perkin Elmer, Waltham, MA, USA). Analytical RP-HPLC made use of a Jupiter Pro-
teo 10μm C18 250x4.6 mm column (Phenomenex, Torrance, CA, USA), monitoring at 220
and 280 nm, flow rate 1.3 mL/min, and the solvent system H2O/0.1% TFA (A) and CH3CN/
0.1% TFA (B), with a linear gradient 5–60% B over 30 min. Peptide purification was performed
by semi-preparative RP-HPLC on a Jupiter Proteo 90 Å C18 column (10x250 mm, 10 μm)
(Phenomenex, Torrance, CA, USA), using a linear gradient 5–60% B over 25 min, with a flow
rate of 10 mL/min. The identity (peptide molecular weight 1311.8) and the peptide purity
(98%) were assessed by HPLC-ESI+-MS analysis. MS scan was performed in the mass range
200–3000 m/z. The raw materials used for peptide synthesis and purification are listed in
Supporting Infromation, S1 Appendix 1. Lastly, a100 μM solution of VRPMPLQ peptide was
prepared.
Patients
Between March 2015 and March 2016, patients undergoing surveillance colonoscopy for long-
standing UC and presenting endoscopically resectable lesions within colitis were considered
for enrollment. The presence of quiescent UC at endoscopy (Mayo Ulcerative Colitis Endo-
scopic Score of Severity) [18] was required for inclusion.
Endoscopy
All patients underwent colonoscopy preparation using a polyethylene glycol-based solution.
Conscious sedation was obtained by administration of intravenous midazolam. Endoscopic
examinations consisted of ileo-colonoscopies and were performed usingOlympus CF-HQ190
or CF TYPE Q180AL/I colonoscopes. After cecal intubation, the colonoscope was slowly with-
drawn and the mucosa carefully inspected for endoscopically visible lesions. Lesions were
classified according to the ASGE Standards of Practice Committee Guideline for the role of
endoscopy in inflammatory bowel disease [19]. Lesions suspicious for dysplasia were evaluated
for endoscopic resectability. Polypoid and non-polypoid lesions with distinct borders and
without endoscopic features of submucosal invasion were removed en-bloc by endoscopic
mucosal resection. Biopsies were obtained from flat and normal appearing mucosa surround-
ing the resection site.
Ex-vivo tissue imaging
Specimens were rinsed with water and then sprayed with the 100μVRPMPLQ peptide solution
within 15 min after excision. After an incubation time of 10 minutes [15], specimens were
rinsed again to remove the excess of peptide not specifically bound to the tissue. CLE examina-
tion was then performed, moving the probe close to the mucosal surface of the specimen. The
examination was carried-out with the Cellvizio1 Endomicroscopy System (Mauna Kea Tech-
nologies, Paris, France), which uses a 2.5-mm catheter probe (Coloflex UHD-type probe). This
system has a field of view of 240 x 200 μm, with a lateral resolution of 1 μm. CLE images were
collected at a scan rate of 12 frames per second with a scanning field of 30,000 pixels.
At the end of the CLE examination, specimens were fixed in 10% formalin and processed
for routine histological examination. Each specimen was classified according to the site of exci-
sion and was then assigned a unique number to enable the matching and comparison of histo-
logical hematoxylin-eosin sections with the corresponding CLE images.
Mosaic reconstructions were carried out using the Cellvizio1 Viewer software, version
1.6.2 (Mauna Kea Technologies, Paris, France).
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Ethical considerations
Patients were excluded in case of age<18 years, refusal to participate or inability to provide
written informed consent, which was obtained from all participants. The study protocol con-
forms to the ethical guidelines of the 1975 Declaration of Helsinki (6th revision, 2008) andhas
been approved by the “Federico II” University of Naples Institutional Review board–Comitato
Etico “C. Romano” (Protocol N.132/2015).
Results
Nine patients were enrolled in the study. All patients had long-standing UC (> 10 years) and
presented quiescent UC [18] at surveillance colonoscopy. A total of 11 lesions were obtained
from the enrolled patients. In particular, 7 polypoid lesions and 4 non-polypoid were detected
at endoscopy and eventually resected. At definitive histology, 4 lesions were diagnosed as
inflammatory psudo-polyps, 6 as dysplastic lesions (low-grade dysplasia) and one as invasive
cancer (SM3). Table 1 shows the histological characteristics of the collected lesions.
Ex-vivo VRPMPLQ-enhanced CLE
In non-dysplastic mucosa, the fluorescence signal was observed in areas corresponding to
peri-cryptal spaces. Crypts were therefore highlighted in negative (Fig 1).
In case of inflammatory polyps, CLE findings of the lesion together with the flat surround-
ing tissue were similar to non-dysplastic mucosa, showing passive accumulation of the fluores-
cent peptide in the enlarged inter-crypt spaces and in the lumen of the crypts (Fig 2).
On the other hand, in presence of dysplasia, active binding of the peptide to dysplastic colo-
nocytes was observed (Fig 3, Fig 4).
Discussion
Several studies have assessed the feasibility of detecting colonic dysplasia using targeted fluo-
rescent probes [17]. Antibodies against specific antigens or peptides showing binding affinity
for dysplastic tissue have been tested in animal models of CRC [11,20] and in patients with
sporadic adenomas or CRC [13,15]. In particular, in vivo studies have yielded encouraging
results in terms of sensitivity and specificity [15]. In this promising context, the possibility of
detecting neoplastic changes associated to IBD using molecular CLE has remained unexplored
to date. To our knowledge, this is the first study to assess and confirm the possibility to detect
Table 1. Characteristics of excised lesions as resulted after histological evaluations. For Patient 3 and 7, two different lesions were collected and
analyzed.
Patient Type of lesion Site Histology
1 Polypoid Sigmoid colon Dysplasia







4 Polypoid Right colon Inflammatory pseudo polyp
Non-polypoid Sigmoid colon Inflammatory pseudo polyp







8 Polypoid Left colon Dysplasia
9 Non-polypoid Sigmoid colon Inflammatory pseudo polyp
https://doi.org/10.1371/journal.pone.0180509.t001
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UC-associated dysplasia at ex-vivo CLE examination using a molecular staining probe. In par-
ticular, we used the fluorescein-conjugated VRPMPLQ peptide as a molecular probe. This is a
phage-derived heptapeptide that has been reported to highlight sporadic colonic dysplasia in
vivo during CLE.15In this study, for the first time, the VRPMPLQ peptide has demonstrated
to be able to detect also the dysplasia associated with Ulcerative Colitis. We believe this result
is far from being obvious. Indeed, VRPMPLQ was originally selected because of its binding
affinity to sporadic adenomatous polyps [15]. Like most sporadic cancers, sporadic adenoma-
tous polyps are usually sustained by a chromosomal instabilitypathway [21],while neoplastic
changes in UC are more frequently associated to the microsatellite instability pathway [22].
These different genetic pathways result in different phenotypes [23] that might result in
different affinity for this probe, due to differential expression of the molecular target of the
VRPMPLQ peptide, that is unknown yet [15].
In the present study the specificity of the probe for dysplasia areas was corroborated by the
different distribution of the peptide observed depending on the absence or presence of dyspla-
sia itself, as determined by traditional histology. In absence of dysplasia, a passive accumula-
tion of the peptide in the lumen crypts and peri-cryptal spaces was observed, as previously
described [15]. Thanks to this passive distribution pattern, the tissue architecture (i.e. crypts)
is highlighted in negative contrast. Conversely, in the presence of dysplasia, active binding of
the peptide to the colonocytes was observed. These findings open new scenarios in the
Fig 1. Non-dysplastic mucosa at CLE with heptapeptide (VRPMPLQ). A series of VRPMPLQ/CLE
images from different patients showing non-dysplastic colonocytes. The fluorescence signal is seen
emanating from areas corresponding to the pericryptal spaces and, to a much lesser extent, from the crypts-
lumen. Crypts are highlighted in negative.
https://doi.org/10.1371/journal.pone.0180509.g001
Fig 2. Non-dysplastic lesion. NBI-endoscopic view showing a polypoid lesion (Is, Paris classification) of the
right colon (A). After resection and coloration with the 100μVRPMPLQ peptide solution, CLE shows
accumulation of the fluorescent peptide in the enlarged inter-crypt spaces and in the lumen crypts. Crypts are
therefore highlighted in negative (B). Conventional histology (haematoxylin/eosin, original magnification, X
106) showing inflammatory psudopolyp (C).
https://doi.org/10.1371/journal.pone.0180509.g002
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management of lesions discovered in the context of UC. In presence of an endoscopically
resectable lesion, topic application of the fluorescent VRPMPLQ peptide could allow a precise
definition of the lesion borders, avoiding positive resection margins. Certainly, this theoretical
advantage need to be proved by comparative studies on a larger number of lesions. Further-
more, it would allow a detailed examination of the flat mucosa surrounding the lesion, looking
for further dysplasia to be discovered, thus orienting biopsies and avoiding unnecessary resec-
tions, when not indicated. In addition, topical administration of this molecular contrast avoids
intravenous administration of fluorescein, thereby avoiding its adverse systemic effects, and
enabling CLE in patients in whom administration of systemic fluorescein is contraindicated
[24,25].
Further studies on larger population of UC patients are needed to estimate the accuracy
and the additional value of targeted CLE compared to chromoendoscopy alone, also in terms
of cost/benefits. Indeed, the use of CLE in cancer surveillance remains restricted to suspicious
areas highlighted by methylene blue or indigo carmine, because examination of the whole
colonic mucosa by CLE remains impracticable [7]. Wanders and colleagues found that the
Fig 3. Dysplastic mucosa at CLE with heptapeptide (VRPMPLQ). A series of VRPMPLQ/CLE images
from different patients showing dysplastic colonocytes.The active binding of the peptide to the colonocytes is
observed and determinates a strong increase in fluorescence.
https://doi.org/10.1371/journal.pone.0180509.g003
Fig 4. Dysplastic lesion. White-light endoscopic view showing a polypoid lesion (Is, Paris classification) of
the transverse colon (A). After resection and coloration with the 100μ VRPMPLQ peptide solution, CLE shows
active binding of the peptide to dysplastic colonocytes is observed. This along with passive accumulation of
the peptide determines an increase in fluorescence (B). Conventional histology (haematoxylin/eosin, original
magnification, X 106) showing low-grade dysplasia (C).
https://doi.org/10.1371/journal.pone.0180509.g004
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combination of chromoendoscopy and CLE has limited applicability in the surveillance of IBD
patients due to a low sensitivity (0.43) [26]. However, their study was hindered by the frequent
technique failure of the endoscope-integrated system of CLE (iCLE) used by the authors. The
iCLE system integrates the CLE in the tip of the endoscope, in contrast with the probe-based
CLE (pCLE), used in this study, where a CLE probe is advanced through the working channel
of a standard endoscope. On the contrary, Duglosz and colleagues found good accuracy of
pCLE in differentiating neoplastic from non-neoplastic mucosa during surveillance in patients
with IBD with high sensitivity (0.89) [26]. A major drawback of the CLE investigation of
inflamed mucosa is the risk of false positives for dysplasia due to inflammatory changes as
crypt destruction and fluorescein leakage, which can be misdiagnosed as dysplasia [27,28].
Hence, molecular CLE could improve the specificity of classical CLE in the presence of inflam-
mation thanks to the specificity of the binding probe-dysplasia.
There are several limitations to this study, although most of them are intrinsic to feasibility
studies. First, this is a pilot study limited to an ex-vivo investigation, as required by the local
ethics committee. Given the experience of Hsiung et al. [15], we are confident that topical
administration in-vivo of the peptide would highlight dysplastic colonocytes in UC patients as
well. Nevertheless, this will be the next step of our research. Second, a control peptide was not
used to test the specificity of the binding. Indeed, we relied on the observation of Hsiung et al.
[15] and the peptide also showed a different pattern of distribution on non-dysplastic lesions.
Third, the study was limited to UC patients with quiescent disease. Indeed, the presence of an
inflamed mucosa could affect the peptide binding. Increased mucosal permeability and inter-
crypt distance might favour passive accumulation of the peptide (i.e., non-specific binding),
making it difficult to differentiate between active and passive binding. In addition, safety issues
might emerge in case of in-vivo administration in patients with active disease. Although pep-
tides have been preferred to antibodies in view of their reduced immunogenicity [17], the
quota of systemic absorption might increase in the presence of altered mucosa. Lastly, we
tested the peptide on a small population of lesions in UC patients. These lesions might not
account for the entire variety of lesions in terms of genotype and phenotype that might be
found in UC patients.
In conclusion, the VRPMPLQ peptide is a promising probe for the detection of dysplasia in
the context of IBD. Further in vivo studies on larger populations are required to evaluate the
effective contribution of this molecular probe in the management of lesions found during sur-
veillance of UC patients.
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